Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — H.C. Wainwright 25th Annual Global Investment Conference 2023
24 slides from Aethlon Medical's conference presentation, September 2023
Slide 1: H.C. Wainwright 25th Annual Global Investment Conference
H.C. Wainwright 25th Annual Global Investment Conference September 2023 Nasdaq: AEMD www.AethlonMedical.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This investor presentation contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this presentation are forward-looking statements, including
Slide 3: Investment Highlights
Investment Highlights • Focused on combating cancer, infectious diseases and organ transplantation with development of first-in-class immunotherapeutic technology • Led by seasoned industry executives with extensive development and commercialization experience • The Aethlon Hemopurifier® has demonst
Slide 4: Key Financial Highlights
Key Financial Highlights • Approximately $12.9 million in cash as of June 30, 2023 • No debt on balance sheet • Approximately 24.8 million shares outstanding • Market capitalization of $7.2 million, as of August 21, 2023 • Trading on Nasdaq under the ticker AEMD 4
Slide 5: Senior Management Team Has Extensive Experience With Both Medical Devices And Therapeutics Companies
Senior Management Team Has Extensive Experience With Both Medical Devices And Therapeutics Companies Charles J. Fisher, Jr., MD, FACP, FCCP, FCCM, Chief Executive Officer • Academic & Industry thought leader in sepsis & inflammation • Head of critical care—Cleveland Clinic • 35 years industry develo
Slide 6: The Aethlon Hemopurifier
The Aethlon Hemopurifier® FDA Designated “Breakthrough Device” In Viral And Oncology Indications • Safely administered in 156 Hemopurifier sessions in 36 patients • Proprietary, patented technology • Clears life-threatening viruses • Designed to clear tumor-derived EVs (Oncology) 6
Slide 7: The Hemopurifier Captures Viruses And Extracellular Vesicles Via Extracorporeal Circuit
The Hemopurifier Captures Viruses And Extracellular Vesicles From A Patient’s Blood Via Extracorporeal Circuit Potential Therapeutic Applications: • Cancer • Life-threatening viral infections • Organ Transplantation 7
Slide 8: Pipeline Targeting Multiple Indications
Pipeline Targeting Multiple Indications Early Feasibility Indication Pre-Clinical Pivotal Study Study India COVID-19 Ongoing Viral Infections Completed HCV Single patient case study, HIV Completed Emergency Use COVID-19, Ebola Expected to begin in Oncology Solid Tumors Australia in early failing ant
Slide 9: Rationale For Removal Of Tumor-derived Extracellular Vesicles By Hemopurifier To Treat Cancer
Rationale Exists For The Removal Of Tumor-derived Extracellular Vesicles (EVs) By Aethlon’s Hemopurifier To Treat Cancer Exosomes are 50-150nm extracellular vesicles (EVs) that are released by all cell types, including tumor cells Specifically, EVs: • Have been shown to contribute to the spread of c
Slide 10: In Vitro Removal Of Cancer-Derived EVs Has Been Demonstrated
In Vitro Removal Of Cancer-Derived EVs Has Been Demonstrated • A scaled down version of the Hemopurifier was operated by recirculating samples of cancer patients' plasma through the hollow fiber filters • The EVs remaining in plasma were quantified • The scaled down Hemopurifier was effective for cl
Slide 11: Clinical Development Plans Underway In Oncology
Clinical Development Plans Underway In Oncology • A new clinical trial in oncology is planned to include multiple tumor types, as well as dosing intervals, to help direct the development of Aethlon’s Hemopurifier as a treatment option in oncology • Aethlon has contracted with NAMSA, a major global C
Slide 12: Rationale For Hemopurifier Treatment In Severe COVID-19 Infections
Recent Scientific & Clinical Literature Provide A Rationale For Hemopurifier Treatment In Severe COVID –19 Infections • COVID viremia is detected in ~34% of patients and is associated with severity, requirement for ICU stay, development of multi-organ failure and poor outcomes • Direct viral injury
Slide 13: In Vitro Removal of clinically relevant SARS-CoV-2 variants by an affinity resin
In Vitro Removal of clinically relevant SARS-CoV-2 variants by an affinity resin containing Galanthus nivalis agglutinin (GNA) ⮚ Columns packed with 1gm of GNA affinity resin ⮚ 5ml of COVID variant in PBS buffer at a concentration of 1 X 104 PFU/ml= 5X104 PFU challenge Table 2. Average Column Captur
Slide 14: In Vivo Removal of SARS-CoV-2 in an Emergency Use Patient
In Vivo Removal of SARS-CoV-2 in an Emergency Use Patient Viremic patient in the ICU with critical disease • Request received from Hoag Newport Beach Hospital (Usman Shah, M.D.) on 14 Jan 2021 • 67-year-old male with PMH of Tetralogy of Fallot, CAD and DM admitted on 6 JAN 2021 with hypoxia and SOB
Slide 15: Evidence of SARS-CoV-2 Capture and Clearance by Hemopurifier
Evidence of SARS-CoV-2 Capture and Clearance by Hemopurifier • Independent Physician Assessment confirmed request for ESTIMATE HEMOPURIFIER CAPTURE emergency use 14 JAN 2021 • IRB approval and Signed Inform Consent obtained (14 JAN 2021) 1 PCR Rxn Total RNA Total Trizol Total Hemopurifier • Patient
Slide 16: Demonstrated Reduction Of Total EVs And Harmful Cargo In An Emergency Use COVID-19 Patient
Demonstrated Reduction Of Total EVs And Harmful Cargo In An Emergency Use COVID-19 Patient Treated With Hemopurifier Total EV’s and Exosomal miRNA over time: Exosomes and miR-424 Exosomes and miR-16 Normalized Exosomal miRNA/ml Plasma Normalized Exosome miRNA/ml plasma 0.6 1.4E+12 0.14 1.4E+12 0.5 1
Slide 17: COVID-19 India Trial Update
COVID-19 India Trial Update: Treatment Of SARS-CoV-2 Infection In Humans With Hemopurifier Device • Regulatory agency in India has approved the use of Hemopurifier devices for clinical trial use • Studying ICU patients with severe or life-threatening disease • Designed to include up to 15 patients a
Slide 18: Hemopurifier Clinical Development Summary
Hemopurifier Clinical Development Summary Oncology Viral Infections • Safety, feasibility and dose • Clinical trial of finding study in solid Hemopurifier in severe tumors failing anti-PD-1 COVID-19 infection antibodies • Currently underway in India • To be initiated first in Australia and then in t
Slide 19: Organ Transplantation: Viral Therapeutic Targets
Organ Transplantation: Viral Therapeutic Targets • Human viruses: • Porcine Viruses (Xenotransplant): • CMV • Porcine Endogenous Retroviruses (PERVs) A, B, C • EBV • Porcine CMV (pCMV) • HBV • Porcine Lymphotrophic Herpes Virus (pLHV) • HCV • HIV • HSV • VZV • HHV 6,7, 8 • SARS-CoV2 Spike Protein •
Slide 20: Extracellular Vesicles are Implicated in Ischemia Reperfusion Injury and Delayed Graft Function
Extracellular Vesicles are Implicated in Ischemia Reperfusion Injury and Impact Delayed Graft Function (DGF) • Delayed Graft Function is the need for dialysis in the 1st week post kidney transplant • DGF occurs in 23-34% of patients getting kidneys from deceased donors • Gremmels and Van Balkom note
Slide 21: Extracellular Vesicles are Implicated in Acute Organ Rejection
Extracellular Vesicles are Implicated in Acute Organ Rejection • Leading hypothesis is that EVs from organ donors carrying MHC molecules are implicated in acute rejection • Kumar and colleagues have demonstrated that donor EVs containing mismatched HLA and Tissue ags were implicated in Lung transpla
Slide 22: Pre-Clinical Translational Activities in Transplantation
Pre-Clinical Translational Activities in Transplantation Examining: • The compatibility of machine perfusion solution with Hemopurifier • Removal of Hepatitis C virus from viremic organs by Hemopurifier • Removal of EVs and exosomal cargo in organ perfusates by Hemopurifier • The downstream effect o
Slide 23: Investment Summary
Investment Summary ▪ Developing novel, patented Hemopurifier blood purification device ▪ Early clinical trials have demonstrated virus and EV clearance both in vitro and in patients ▪ Granted two FDA “Breakthrough Device” designations ▪ Focused on multiple therapeutic targets in cancer, viral diseas
Slide 24: Contact Information
Contact Information 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 619.941.0360 Nasdaq: AEMD www.AethlonMedical.com This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our produ
Aethlon Medical — H.C. Wainwright 25th Annual Global Investment Conference 2023 on 6ix